Gengqian Cai

Predictive models of choroidal neovascularization and geographic atrophy incidence applied to clinical trial design.

Chun-Fang Xu, J. Whittaker, S. Stinnett, 2012, American journal of ophthalmology.

Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging.

Z. Fayad, M. Farkouh, Esad Vucic, 2014, Journal of the American College of Cardiology.

Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial

Manesh R. Patel, L. Newby, C. Granger, 2014, The Lancet.

Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

J. H. Rudd, Z. Fayad, F. Gleeson, 2012, JACC. Cardiovascular imaging.

OP-NDTJ190087 599..606

R. B. Henderson, C. Savage, L. Willcocks, 2020 .

Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy

R. B. Henderson, C. Savage, L. Willcocks, 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

A systematic review and meta-analysis to compare the efficacy of acyclovir 3% ophthalmic ointment to idoxuridine in curing herpetic keratitis by Day 7 of treatment

J. Wurzelmann, M. McLaughlin, M. Fries, 2015, BMC Ophthalmology.

Modified Simes’ critical values under positive dependence

S. Sarkar, Gengqian Cai, 2006 .

Sample Size Determination With False Discovery Rate Adjustment for Experiments With High-Dimensional Data

Xiwu Lin, Kwan R. Lee, Gengqian Cai, 2010 .

SaO022EFFECT OF BELIMUMAB ON PROTEINURIA AND ANTI-PLA2R AUTOANTIBODY IN IDIOPATHIC MEMBRANOUS NEPHROPATHY - 6 MONTHS DATA

P. Brenchley, C. Savage, L. Willcocks, 2015 .

Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers.

A. McGeoch, D. Sprecher, J. Graggaber, 2013, British journal of clinical pharmacology.